Veracyte | VCYT - Current Assets


Veracyte reported $574.78M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Agenus USD 95.28M 38.15M Mar/2026
Agilent USD 4.76B 148M Mar/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Bruker USD 2.22B 121.4M Jun/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Illumina USD 2.83B 96M Jun/2026
Intrexon USD 23.72M 45.04M Jun/2024
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Laboratory Of America USD 3.81B 743.9M Jun/2026
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
Myriad Genetics USD 289M 23.8M Jun/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Siemens EUR 65.14B 3.81B Jun/2026
Sonic Healthcare AUD 2.3B 52.76M Dec/2024
Thermo Fisher Scientific USD 23.36B 1.05B Jun/2026
Veracyte USD 574.78M 52.6M Jun/2026
Waters USD 3.9B 186M Jun/2026